The Body Covers: The 41st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy
Conference Summaries: Day Two
Monday, December 17, 2001
- HIV Session I (Slide Session 071)
- Tenofovir DF: A 24-Week Interim Analysis from a Phase III Double-Blind, Placebo-Controlled Study in Antiretroviral-Experienced Patients (Abstract 666)
Coverage by Calvin J. Cohen, M.D., M.S.
- Comparative Results (Phase II 48-Week): BMS-232632, Stavudine, Lamivudine as HAART for Treatment-Naive HIV-Positive Patients (AI424-008) (Abstract 667)
Coverage by Brian A. Boyle, M.D., J.D.
- TMC125 Is a Highly Potent Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) in Antiretroviral Therapy (ART)-Naive, HIV-1 Infected Subjects (Abstract 668)
Coverage by Douglas T. Dieterich, M.D.
- Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors and Antiretroviral History Do Not Affect Virologic Response to T-1249 (Abstract 669)
Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.
- Switch to Trizivir Versus Continued HAART Provides Equivalent HIV-1 RNA Suppression at 48 Weeks (TRIZAL - AZL30002) (Abstract 671)
Coverage by Douglas T. Dieterich, M.D.
- Hepatitis Viruses (Poster Session 077)
- Immunopathogenesis of HIV Infection (Symposium 108)